DC-1-192

DC-1-192 is a novel C8-linked benzofused pyrrolo[2,1-c][1,4]benzodiazepine monomeric hybrid designed as a small molecule inhibitor of nuclear factor-kappa B (NF-κB) DNA binding. It exhibits potent inhibitory effects on both the canonical and non-canonical NF-κB pathways in preclinical models of chronic lymphocytic leukemia (CLL) and multiple myeloma. DC-1-192 has demonstrated low nanomolar LD50 values in primary CLL and multiple myeloma cell lines. Notably, in vivo studies using a human multiple myeloma xenograft model showed that DC-1-192 significantly prolonged survival. The drug's efficacy may correlate with certain genetic mutations such as BIRC3 or NOTCH1, which increase cellular sensitivity. Additionally, DC-1-192 showed synergy with bortezomib and ibrutinib, particularly in microenvironments mimicking lymph node conditions. These findings highlight its potential in overcoming resistance mechanisms in NF-κB-driven cancers, especially in relapsed or refractory disease contexts[1][9].